BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26059187)

  • 1. Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis.
    Bellini A; Bernard V; Leroy Q; Rio Frio T; Pierron G; Combaret V; Lapouble E; Clement N; Rubie H; Thebaud E; Chastagner P; Defachelles AS; Bergeron C; Buchbinder N; Taque S; Auvrignon A; Valteau-Couanet D; Michon J; Janoueix-Lerosey I; Delattre O; Schleiermacher G
    Clin Cancer Res; 2015 Nov; 21(21):4913-21. PubMed ID: 26059187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment.
    Javanmardi N; Fransson S; Djos A; Sjöberg RM; Nilsson S; Truvé K; Kogner P; Martinsson T
    Sci Rep; 2019 Feb; 9(1):2199. PubMed ID: 30778092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of new ALK mutations at relapse of neuroblastoma.
    Schleiermacher G; Javanmardi N; Bernard V; Leroy Q; Cappo J; Rio Frio T; Pierron G; Lapouble E; Combaret V; Speleman F; de Wilde B; Djos A; Ora I; Hedborg F; Träger C; Holmqvist BM; Abrahamsson J; Peuchmaur M; Michon J; Janoueix-Lerosey I; Kogner P; Delattre O; Martinsson T
    J Clin Oncol; 2014 Sep; 32(25):2727-34. PubMed ID: 25071110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of tumor ALK status in neuroblastoma patients using peripheral blood.
    Combaret V; Iacono I; Bellini A; Bréjon S; Bernard V; Marabelle A; Coze C; Pierron G; Lapouble E; Schleiermacher G; Blay JY
    Cancer Med; 2015 Apr; 4(4):540-50. PubMed ID: 25653133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
    De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
    Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic anaplastic lymphoma kinase (ALK) mutation in neuroblastomas and other pediatric tumors.
    Kwon MJ; Choi YL; Sung KW; Kang SY; Park SM; Choi SY; Kim JS; Suh YL
    Pathol Res Pract; 2011 Oct; 207(10):634-9. PubMed ID: 21940108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical feature of anaplastic lymphoma kinase-mutated neuroblastoma.
    Ogura T; Hiyama E; Kamei N; Kamimatsuse A; Ueda Y; Ogura K
    J Pediatr Surg; 2012 Oct; 47(10):1789-96. PubMed ID: 23084186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
    Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
    PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seek and Ye Shall Find: Subclonal Anaplastic Lymphoma Kinase Mutations.
    George RE
    Clin Cancer Res; 2015 Nov; 21(21):4747-9. PubMed ID: 26362998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.
    Chen L; Humphreys A; Turnbull L; Bellini A; Schleiermacher G; Salwen H; Cohn SL; Bown N; Tweddle DA
    Oncotarget; 2016 Dec; 7(52):87301-87311. PubMed ID: 27888620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency and Prognostic Impact of
    Bellini A; Pötschger U; Bernard V; Lapouble E; Baulande S; Ambros PF; Auger N; Beiske K; Bernkopf M; Betts DR; Bhalshankar J; Bown N; de Preter K; Clément N; Combaret V; Font de Mora J; George SL; Jiménez I; Jeison M; Marques B; Martinsson T; Mazzocco K; Morini M; Mühlethaler-Mottet A; Noguera R; Pierron G; Rossing M; Taschner-Mandl S; Van Roy N; Vicha A; Chesler L; Balwierz W; Castel V; Elliott M; Kogner P; Laureys G; Luksch R; Malis J; Popovic-Beck M; Ash S; Delattre O; Valteau-Couanet D; Tweddle DA; Ladenstein R; Schleiermacher G
    J Clin Oncol; 2021 Oct; 39(30):3377-3390. PubMed ID: 34115544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma.
    Schulte JH; Bachmann HS; Brockmeyer B; Depreter K; Oberthür A; Ackermann S; Kahlert Y; Pajtler K; Theissen J; Westermann F; Vandesompele J; Speleman F; Berthold F; Eggert A; Brors B; Hero B; Schramm A; Fischer M
    Clin Cancer Res; 2011 Aug; 17(15):5082-92. PubMed ID: 21632861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking.
    Mazot P; Cazes A; Boutterin MC; Figueiredo A; Raynal V; Combaret V; Hallberg B; Palmer RH; Delattre O; Janoueix-Lerosey I; Vigny M
    Oncogene; 2011 Apr; 30(17):2017-25. PubMed ID: 21242967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALK amplification and protein expression predict inferior prognosis in neuroblastomas.
    Wang M; Zhou C; Sun Q; Cai R; Li Y; Wang D; Gong L
    Exp Mol Pathol; 2013 Oct; 95(2):124-30. PubMed ID: 23797004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [ALK gene mutations in childhood neuroblastoma].
    Yang CL; Yue LJ; Jiang XP; Wen FQ; Zheng MM
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 Oct; 14(10):763-6. PubMed ID: 23092569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors.
    Bagci O; Tumer S; Olgun N; Altungoz O
    Cancer Lett; 2012 Apr; 317(1):72-7. PubMed ID: 22085494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Impact of
    O'Donohue T; Gulati N; Mauguen A; Kushner BH; Shukla N; Rodriguez-Sanchez MI; Bouvier N; Roberts S; Basu E; Cheung NK; Modak S
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.
    Fransson S; Hansson M; Ruuth K; Djos A; Berbegall A; Javanmardi N; Abrahamsson J; Palmer RH; Noguera R; Hallberg B; Kogner P; Martinsson T
    Genes Chromosomes Cancer; 2015 Feb; 54(2):99-109. PubMed ID: 25251827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Abnormality of anaplastic lymphoma kinase gene and its expression in pediatric neuroblastoma].
    Chen S; Zhou C; Ma X; Gong L
    Zhonghua Bing Li Xue Za Zhi; 2014 Aug; 43(8):541-5. PubMed ID: 25346125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of ALK hotspot mutations in relapsed neuroblastoma.
    Allinson LM; Potts A; Goodman A; Bown N; Bashton M; Thompson D; Basta NO; Gabriel AS; McCorkindale M; Ng A; McNally RJQ; Tweddle DA
    Genes Chromosomes Cancer; 2022 Dec; 61(12):747-753. PubMed ID: 36029175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.